Cite
HARVARD Citation
Hashimoto, Y. et al. (2022). Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial. Expert opinion on drug safety. 21 (12), pp. 1495-1503. [Online].